Improta-Caria AC, Ferrari F, Gomes JLP, Villalta PB, Soci ÚPR, Stein R, Oliveira EM. Dysregulated microRNAs in type 2 diabetes and breast cancer: Potential associated molecular mechanisms. World J Diabetes 2024; 15(6): 1187-1198 [PMID: 38983808 DOI: 10.4239/wjd.v15.i6.1187]
Corresponding Author of This Article
Alex Cleber Improta-Caria, MSc, PhD, Professor, Researcher, Laboratory of Biochemistry and Molecular Biology of the Exercise, Physical Education and Sport School, University of São Paulo, 65 Vila Universitaria, São Paulo 05508-030, Brazil. alexcaria.personal@hotmail.com
Research Domain of This Article
Pathology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Diabetes. Jun 15, 2024; 15(6): 1187-1198 Published online Jun 15, 2024. doi: 10.4239/wjd.v15.i6.1187
Dysregulated microRNAs in type 2 diabetes and breast cancer: Potential associated molecular mechanisms
Alex Cleber Improta-Caria, Filipe Ferrari, João Lucas Penteado Gomes, Paloma Brasilio Villalta, Úrsula Paula Renó Soci, Ricardo Stein, Edilamar M Oliveira
Alex Cleber Improta-Caria, João Lucas Penteado Gomes, Úrsula Paula Renó Soci, Edilamar M Oliveira, Laboratory of Biochemistry and Molecular Biology of the Exercise, Physical Education and Sport School, University of São Paulo, São Paulo 05508-030, Brazil
Filipe Ferrari, Ricardo Stein, Graduate Program in Cardiology and Cardiovascular Sciences, Federal University of Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, Porto Alegre 90035003, Brazil
Paloma Brasilio Villalta, Laboratory of Metabolic Disorders (Labdime), School of Applied Sciences, University of Campinas-UNICAMP, Campinas 13484-350, Brazil
Edilamar M Oliveira, Departments of Internal Medicine, Molecular Pharmacology and Physiology, Center for Regenerative Medicine, USF Health Heart Institute, Morsani College of Medicine, University of South Florida, Tampa, FL 33602, United States
Author contributions: Improta-Caria AC and Oliveira EM designed the research; Improta-Caria AC, Ferrari F, Gomes JLP, Villalta PB and Soci UPR performed the research; Improta-Caria AC, Ferrari F, Gomes JLP, Villalta PB and Soci UPR wrote the paper; Improta-Caria AC, Ferrari F, Gomes JLP, Villalta PB, Soci UPR, Stein R and Oliveira EM analyzed the data; Improta-Caria AC, Stein R and Oliveira EM supervised the intellectual content.
Supported bySao Paulo Research Foundation, No. 2022/02339-4; and Conselho Nacional de Desenvolvimento Científico e Tecnológico, No. 313376/2021-2 and No. 313479/2017-8.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Alex Cleber Improta-Caria, MSc, PhD, Professor, Researcher, Laboratory of Biochemistry and Molecular Biology of the Exercise, Physical Education and Sport School, University of São Paulo, 65 Vila Universitaria, São Paulo 05508-030, Brazil. alexcaria.personal@hotmail.com
Received: December 31, 2023 Revised: March 3, 2024 Accepted: April 26, 2024 Published online: June 15, 2024 Processing time: 162 Days and 16.8 Hours
Abstract
Type 2 diabetes (T2D) is a multifaceted and heterogeneous syndrome associated with complications such as hypertension, coronary artery disease, and notably, breast cancer (BC). The connection between T2D and BC is established through processes that involve insulin resistance, inflammation and other factors. Despite this comprehension the specific cellular and molecular mechanisms linking T2D to BC, especially through microRNAs (miRNAs), remain elusive. miRNAs are regulators of gene expression at the post-transcriptional level and have the function of regulating target genes by modulating various signaling pathways and biological processes. However, the signaling pathways and biological processes regulated by miRNAs that are associated with T2D and BC have not yet been elucidated. This review aims to identify dysregulated miRNAs in both T2D and BC, exploring potential signaling pathways and biological processes that collectively contribute to the development of BC.
Core Tip: "Dysregulated microRNAs (miRNAs) in Type 2 diabetes (T2D) and breast cancer (BC): Potential Associated Molecular Mechanisms" is an innovative work that seeks to elucidate cellular and molecular mechanisms associated with T2D and BC regulated by miRNAs. Several dysregulated miRNAs were identified in both diseases and subsequently we created a Venn diagram identifying 9 overlapping miRNAs in the two diseases. Finally, we carried out an exploratory analysis of these 9 miRNAs and with the help of DIANA Tools we created a heatmap showing biological processes regulated by these miRNAs.
